Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 401–500 of 1,000
Shehatta, N. H., Okda, T. M., Omran, G. A., & Abd-Alhaseeb, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112599 · Cited by 59
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer
Warusavitarne, J. H., & Schnitzler, M. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0228-0 · Cited by 56
“Cells with mutated p53 have been shown to be resistant to 5FU-induced apoptosis [72, 73].”
Zhang, H., Shi, X., Zhang, Q.-J., Hampong, M., Paddon, H. B., Wahyuningsih, D. H., & Pelech, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203214200 · Cited by 63
Mbaveng, A. T., Fru, G., Bonsou, I. N., Ombito, J. O., Yeboah, S. O., Kuete, V., & Efferth, T. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113632 · Cited by 56
Can, G., Akpinar, B., Baran, Y., Zhivotovsky, B., & Olsson, M. (2012) · Oncogene · doi:10.1038/onc.2012.467 · Cited by 65
Lehmann‐Che, J., André, F., Desmedt, C., Mazouni, C., Giacchetti, S., Turpin, E., Espié, M., Plassa, L., Marty, M. E., Bertheau, P., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0243 · Cited by 60
MECHANISMS OF CELL-CYCLE CHECKPOINTS: AT THE CROSSROADS OF CARCINOGENESIS AND DRUG DISCOVERY*
Flatt, P. M., & Pietenpol, J. A. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102335 · Cited by 70
Park, S. R., Namkoong, S., Friesen, L., Cho, C., Zhang, Z. Z., Chen, Y., Yoon, E., Kim, C. H., Kwak, H., Kang, H. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108077 · Cited by 57
“Accordingly, 5FU treatment in colon cancer cell lines has been often used to investigate the cancer cell response to DNA damage (Bunz et al., 1999).”
BackgroundAttenuation of the p53 response to DNA damage by high cell density
Bar, J., Cohen-Noyman, E., Geiger, B., & Oren, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207325 · Cited by 59
“…genes, p53 can upregulate the transcription of a number of antiapoptotic genes, such as HB-EGF (Fang et al., 2001) and several decoy receptors (Sheikh et al., 1999; Meng et al., 2000), and induction of p21WAF1 by p53 can also confer increased resistance to cytotoxic therapy (Bunz et al., 1999).”
BackgroundWallace, M., Coates, P. J., Wright, E. G., & Ball, K. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204496 · Cited by 55
“Whether p21, per se, is able to prevent apoptosis or whether it acts solely by promoting G1-arrest is unclear.”
BackgroundInfluentialLin-Lee, Y.-C., Tatebe, S., Savaraj, N., Ishikawa, T., & Kuo, M. T. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00592-x · Cited by 59
Patel, V., Lahusen, T. J., Leethanakul, C., Igishi, T., Kremer, M., Quintanilla‐Martínez, L., Ensley, J. F., Sausville, E. A., Gutkind, J. S., & Senderowicz, A. M. (2002) · PubMed · Cited by 59
Ye, Z., Fang, J., Dai, S., Wang, Y., Fu, Z., Feng, W., Wei, Q., & Huang, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.023 · Cited by 53
Devlin, H.-L., Mack, P., Burich, R. A., Gumerlock, P. H., Kung, H.-J., Mudryj, M. M., & White, R. D. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2027 · Cited by 54
“Several p53 point mutants that are unable to transactivate the p21 gene are more potent inducers of apoptosis than wild-type p53 to treatment with ionizing radiation (38, 39), UV (40), or doxorubicin (41).”
BackgroundWeiss, M. B., Vitolo, M. I., Mohseni, M., Rosen, D. M., Denmeade, S. R., Park, B. H., Weber, D. J., & Bachman, K. E. (2010) · Oncogene · doi:10.1038/onc.2010.220 · Cited by 56
“However, these cells are less sensitive to the apoptotic effects of the antimetabolite 5-fluorouracil (Bunz et al., 1999).”
BackgroundMeza‐Sosa, K. F., Miao, R., Navarro, F., Zhang, Z., Zhang, Y., Hu, J. J., Hartford, C. C. R., Li, X. L., Pedraza‐Alva, G., Pérez‐Martínez, L., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.001 · Cited by 53
Self-citationThe relevance of drug sequence in combination chemotherapy
Shah, M. A., & Schwartz, G. K. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0165 · Cited by 62
Lomonosova, E. E., Subramanian, T., & Chinnadurai, G. (2005) · Oncogene · doi:10.1038/sj.onc.1208836 · Cited by 56
“The colon cancer cell line HCT116 expresses wt p53 (p53þ /þ ) and an isogenic derivate of this cell line (HCT116 p53 / ) is null for p53 due to disruption of both alleles of p53 by gene targeting (Bunz et al., 1999).”
BackgroundBrooks, K. R., To, K. B., Joshi, M.-B. M., Conlon, D. H., Herndon, J. E., D’Amico, T. A., & Harpole, D. H. (2003) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(03)00131-0 · Cited by 51
Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy
Chowdhury, P., Lin, G. E., Liu, K., Song, Y., Lin, F., & Lin, W.-C. (2014) · Nature Communications · doi:10.1038/ncomms6476 · Cited by 58
Smakman, N., van den Wollenberg, D. J. M., Elias, S. G., Sasazuki, T., Shirasawa, S., Hoeben, R. C., Rinkes, I. H. M. B., & Kranenburg, O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4108 · Cited by 57
“To assess the possible contribution of p53 and mutant h-catenin to colorectal cancer cell killing by ReovirusT3D, we used HCT116derived cell lines in which either mutant h-catenin or p53 was deleted through homologous recombination (8, 9).”
BackgroundMethodInfluentialSer326Cys polymorphism inhOGG1 gene and risk of esophageal cancer in a Chinese population
Xing, D.-Y., Tan, W., Song, N., & Lin, D. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010520)95:3<140::aid-ijc1024>3.0.co;2-2 · Cited by 161
Dudley, A. C., Shih, S.-C., Cliffe, A. R., Hida, K., & Klagsbrun, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604465 · Cited by 50
“…accompanied by deletion of or mutations in p53; however, both drug resistance and increased sensitivity in a p53 null background have been noted (Bunz et al, 1999; Burdelya et al, 2006). p53 is mutated or lost in about half of all cancers probably as a consequence of selection pressure for p53…”
Backgroundp53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations
Sung, Y., Kim, D., & Kim, J. (2022) · Diagnostic Pathology · doi:10.1186/s13000-022-01273-w · Cited by 58
Systems Pharmacology Assessment of the 5-Fluorouracil Pathway
Muhale, F., Wetmore, B. A., Thomas, R. S., & McLeod, H. L. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.188 · Cited by 57
“While in vitro studies demonstrated that loss of p53 confers cell resistance to 5-FU [30], another study demonstrated that increased p53 expression in tumor tissue correlated with 5-FU resistance [31].”
BackgroundXu, B., Guo, X., Mathew, S., Armesilla, A. L., Cassidy, J., Darling, J. L., & Wang, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.10.013 · Cited by 49
“p21 is involved in cell cycle blockage and confers cancer cell resistance to 5-FU [30].”
BackgroundChallenges for MicroRNA Microarray Data Analysis
Wang, B., & Xi, Y. (2013) · Microarrays · doi:10.3390/microarrays2020034 · Cited by 54
Allison, S. J., Cooke, D. J., Davidson, F. S., Elliott, P. I. P., Faulkner, R. A., Griffiths, H. B. S., Harper, O. J., Hussain, O. A., Owen‐Lynch, P. J., Phillips, R. M., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805510 · Cited by 51
Targeting cancer cells by exploiting their resistance
Blagosklonny, M. V. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00111-4 · Cited by 50
Sohn, T. A., Bansal, R. K., Su, G. H., Murphy, K. M., & Kern, S. E. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.949 · Cited by 49
“Syngeneic HCT116 cells, wild-type (HCT116 p53/) and null for TP53 (HCT116 p53–/–), were used since they are the only human pair of syngeneic cells matched for the presence or absence of the wild-type native TP53 gene ( 36 ).”
MethodThe Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA
Sun, J., Sun, Q., Brown, M. F., Dudgeon, C., Chandler, J., Xu, X. M., Shu, Y., Zhang, L., & Yu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043158 · Cited by 52
“The somatic knockout cells lines HCT 116 p53 KO [24], HCT 116 PUMA KO [15], DLD1 PUMA KO [18], HCT 116 FoxO3a stable knockdown (KD) cells and small interfering RNA (siRNA) [19] have been previously described.”
MethodApoptosis in Carcinogenesis and Chemotherapy
Chen, G. G., & Lai, P. B. S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9597-9 · Cited by 60
Venkata Narayanan, I., Paulsen, M. T., Bedi, K., Berg, N., Ljungman, E. A., Francia, S., Veloso, A., Magnuson, B., di Fagagna, F. D., Wilson, T. E., et al. (2017) · Scientific Reports · doi:10.1038/srep43598 · Cited by 48
Jung, H., Seong, H., & Ha, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806225200 · Cited by 57
Bhonde, M. R., Hanski, M.-L., Notter, M., Gillissen, B. F., Daniel, P. T., Zeitz, M., & Hanski, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209017 · Cited by 47
“…the presence/absence of a functional p53 decides whether the cells would undergo cell cycle arrest or apoptosis in response to DNA damage and confirm previous reports on the requirement of p21 for the p53-dependent cell cycle arrest response (Bunz et al., 1999; Han et al., 2002; Yu et al., 2003).”
Borralho, P. M., da Silva, I. M., Aranha, M. M., Albuquerque, C. M., Leitão, C. N., Steer, C. J., & Rodrigues, C. M. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.005 · Cited by 51
“Further, its cytotoxicity has been correlated with the presence of wild-type p53 protein [5,7,8].”
BackgroundResultInfluentialOgi, K., Toyota, M., Mita, H., Satoh, A., Kashima, L., Sasaki, Y., Suzuki, H., Akino, K., Nishikawa, N., Noguchi, M., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1896 · Cited by 47
Saeed, M. E. M., Abdelgadir, H., Sugimoto, Y., Khalid, H. E., & Efferth, T. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.07.005 · Cited by 53
p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
Hopkins-Donaldson, S., Belyanskaya, A. L., Simões‐Wüst, A. P., Sigrist, B., Kurtz, S., Zangemeister‐Wittke, U., & Stahel, R. A. (2006) · Neoplasia · doi:10.1593/neo.06148 · Cited by 54
“apoptosis [45,46], whereas in other systems, increased sen-”
BackgroundNew p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53
Min, S.-H., Deuk‐Su, K. I. M., Heo, Y.-S., Kim, Y., Kim, H., Kim, J., Han, Y.-M., Kim, I.-C., & Yoo, O.-J. (2008) · Oncogene · doi:10.1038/onc.2008.409 · Cited by 48
p53 dependent cell‐cycle arrest triggered by chemotherapy in xenografted breast tumors
Varna, M., Lehmann‐Che, J., Turpin, E., Marangoni, E., Bouchtaoui, M. E., Jeanne, M., Grigoriu, C., Ratajczak, P., Lebœuf, C., Plassa, L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24049 · Cited by 49
Zhao, L., & Liao, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13171-13181.2003 · Cited by 56
“To directly assess the relationship between cytoplasmic sequestration of p53 by the Ad12 55-kDa protein and the ability of p53 to induce apoptosis, we transfected Saos2 cells with vectors expressing p53 and various GFP-E1B constructs and then treated the cells with 5-fluorouracil, which has been demonstrated to elicit…”
MethodSzepesházi, K., Schally, A. V., Halmos, G., Armatis, P. E., Hébert, F., Sun, B., Feil, A., Kiaris, H., & Nagy, A. (2002) · PubMed · Cited by 47
Apoptosis and chemo‐resistance in colorectal cancer
Prabhudesai, S. G., Rekhraj, S., Roberts, G., Darzi, A. W., & Ziprin, P. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20785 · Cited by 52
“In vitro studies have shown that loss of p53 function reduces chemo-sensitivity of colorectal cancer cells to 5-FU [66,67], while others have shown that p53 overexpression in Stage III [68] and Stage IV [69] colorectal cancer patients correlated with resistance to 5-FU based chemotherapy.”
BackgroundDörsam, B., Göder, A., Seiwert, N., Kaina, B., & Fahrer, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1434-0 · Cited by 49
Lin, L.-C., Lee, H.-H., Hwang, W.-S., Li, C., Huang, C., Que, J., Lin, K.-L., Lin, F., & Lu, C. (2006) · Surgical Oncology · doi:10.1016/j.suronc.2007.01.001 · Cited by 46
“p53, p21, p27, and Bcl-2 are four important proteins involved in the control of the cell cycle [2–7].”
BackgroundLe, H.-V., Minn, A. J., & Massagué, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504689200 · Cited by 51
Stevenson, L. S., Allen, W. L., Proutski, I., Stewart, G. E., Johnston, L., McCloskey, K. D., Wilson, P. M., Longley, D. B., & Johnston, P. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020276 · Cited by 52
“The reduced sensitivity of p53 HCT116 cells to 5-FU has been previously noted by our group and others [23,24].”
BackgroundMahyar-Roemer, M., Fritzsche, C., Wagner, S., Laue, M. M., & Roemer, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207637 · Cited by 48
“In agreement with recent reports by Bunz et al. (1999), flow cytometric analysis showed that ADR causes the arrest of the cell cycle in the G2/Mphase within 48 h, but not apoptosis, whereas 5FU induces a substantial peak of cells with a sub-2n DNA content indicative of apoptotic degradation (Figure…”
BackgroundResultInfluentialGenetic disruption ofUSP9Xsensitizes colorectal cancer cells to 5-fluorouracil
Harris, D. R., Pike, A. M., & Bunz, F. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21792 · Cited by 48
“For example, p53-deficient cells exhibit a dramatic loss of 5-FU-induced apoptosis, but only a modest decrease in clonogenic survival after the same treatment.(11) Intuitively, apoptosis triggered in a cell population must decrease clonogenic survival to some extent, but clearly other cellular processes exert consider…”
BackgroundSelf-citationHigh Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs
Krynetskaia, N. F., Xie, H. M., Vučetić, S., Zoran Obradovic, A., & Krynetskiy, E. Y. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.041764 · Cited by 48
“…araC Because chemotherapeutic agents used in this study (FU, araC, and MP) are known to exert their cytotoxic effect via the p53-mediated pathway (Bunz et al., 1999; Zhang et al., 2000, 2007; Yin et al., 2006), we used luciferase reporter plasmids to assess the role of Hmgb1 in transcriptional…”
BackgroundMethodInfluentialLee, K., Lee, D. H., Jung, Y. J., Shin, S. Y., & Lee, Y. H. (2016) · Applied Biological Chemistry · doi:10.1007/s13765-016-0160-0 · Cited by 45
“Wild-type (p53) and p53-null (p53) HCT116 human colon cancer cells (Bunz et al. 1999) were described elsewhere (Shin et al.”
BackgroundInfluentialImmunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics
Elliott, K., McQuaid, S., Salto‐Tellez, M., & Maxwell, P. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203178 · Cited by 45
Oh, H. J., Bae, J. M., Wen, X., Jung, S., Kim, Y.-H., Kim, K. J., Cho, N., Kim, J. H., Han, S., Kim, T., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0429-2 · Cited by 48
Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites
Fedier, A., Schlamminger, M., Schwarz, V. A., Haller, U., Howell, S. B., & Fink, D. A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg240 · Cited by 48
“This contributes to resistance to radiotherapy and to certain chemotherapeutic agents in some tissues [3].”
BackgroundVasilevskaya, I. A., Rakitina, T. V., & O'Dwyer, P. J. (2003) · PubMed · Cited by 45
Wang, W., McLeod, H. L., Cassidy, J., & Collie-Duguid, E. S. R. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0384-5 · Cited by 45
“p53 is a tumour suppressor gene whose genetic status plays a key role in resistance of cancer cells to some anticancer drugs including 5-FU [2].”
BackgroundRNA-Based 5-Fluorouracil Toxicity Requires the Pseudouridylation Activity of Cbf5p
Hoskins, J. W., & Butler, J. S. (2008) · Genetics · doi:10.1534/genetics.107.082727 · Cited by 45
“Several experiments have shown that uridine, not thymidine, relieves the cytotoxic and apoptotic effects of 5FU (Engelbrecht et al. 1984; Linke et al. 1996; Pritchard et al. 1997; Bunz et al. 1999; Hoskins and Butler 2007).”
BackgroundGöder, A., Nagel, G., Kraus, A., Dörsam, B., Seiwert, N., Kaina, B., & Fahrer, J. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv070 · Cited by 47
“response to 5-FU (28) as tested 4 month ago.”
BackgroundCartee, L., Wang, Z., Decker, R. H., Chellappan, S., Fusaro, G., Hirsch, K. G., Sankala, H. M., Dent, P., & Grant, S. (2001) · PubMed · Cited by 52
p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis
Lopez‐Crapez, E., Bibeau, F., Thézenas, S., Ychou, M., Simony-Lafontaine, J., Thirion, A., Azria, D., Grenier, J., & Sénesse, P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602622 · Cited by 46
“Several in vitro (Lowe et al, 1994; Bunz et al, 1999) and in vivo (Lee and Bernstein, 1993; Kemp et al, 2001) studies have demonstrated that p53 dysfunction might restrict therapeutic efficacy.”
BackgroundVariability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma
Aryee, D. N. T., Niedan, S., Ban, J., Schwentner, R., Muehlbacher, K., Kauer, M., Kofler, R., & Kovar, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.635 · Cited by 44
“TP53 mutations may be associated with an aggressive phenotype and poor prognosis, and some p53 mutants counteract the effects of anticancer agents that attack tumours (Bunz et al, 1999; Poeta et al, 2007).”
BackgroundZhao, Y., Luo, A., Li, S., Zhang, W., Chen, H., Li, L., Ding, F., Huang, F., & Liu, Z. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704361 · Cited by 44
“DNA damage, such as that induced by radiation or chemotherapeutic drugs, is a potent activator of p53 (37).”
BackgroundLethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate
Sica, V., Pedro, J. M. B., Izzo, V., Pol, J. G., Pierredon, S., Enot, D. P., Durand, S., Bossut, N., Chery, A., Souquère, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.058 · Cited by 46
Yun, C., Lee, J. H., Park, H., Jin, Y.-M., Park, S., Park, K., & Cho, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203896 · Cited by 44
“It is known that loss of p53 function due to mutation in p53 gene frequently interferes with responses of cancer cells to anticancer therapies and thereby is used as a major predictor of failure in anticancer therapies (reviewed in Weller, 1998; Bunz et al., 1999).”
BackgroundParida, U. K., Biswal, S. K., & Bindhani, B. K. (2014) · Advances in Biological Chemistry · doi:10.4236/abc.2014.46041 · Cited by 43
Chao, T., Zhou, X. Y., Cao, B., Liao, P., Liu, H., Chen, Y., Park, H., Zeng, S. X., & Lu, H. (2016) · Nature Communications · doi:10.1038/ncomms13755 · Cited by 45
Models for Understanding Resistance to Chemotherapy in Liver Cancer
Marin, J. J. G., Herraez, E., Lozano, E., Macias, R. I. R., & Briz, O. (2019) · Cancers · doi:10.3390/cancers11111677 · Cited by 43
“In the case of p53, their role in chemoresistance is not entirely known and seems to depend on both cellular context and the type of the administered drug [126,127], while mutated KRAS is a poor biomarker for prognosis in CCA patients [128].”
BackgroundGmeiner, W. H. (2020) · Cancers · doi:10.3390/cancers12061641 · Cited by 50
“This is significant because the response of CRC cells and induction of apoptosis following 5-FU-treatment depends on p53 expression [106].”
BackgroundRosati, G., Chiacchio, R., Reggiardo, G., Sanctis, D. D., & Manzione, L. (2004) · Tumor Biology · doi:10.1159/000081389 · Cited by 43
Lei, H., & Quelle, F. W. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0531 · Cited by 43
“tained irreparable DNA damage can cause cell death and enhance sensitivity to DNA damaging agents, such as cisplatin (4-6).”
BackgroundHuang, J., Kirk, B. W., Favis, R., Soussi, T., Paty, P. B., Cao, W., & Barany, F. (2002) · Oncogene · doi:10.1038/sj.onc.1205109 · Cited by 44
“Sporadic mutations in the p53 gene in¯uence both clinical outcome and response to therapy (Broll et al., 1999; Bunz et al., 1999; Dameron et al., 1994; Heide et al., 1997; Prives and Hall, 1999; Tortola et al., 1999; Zou et al., 2000).”
BackgroundRusso, P., Malacarne, D., Falugi, C., Trombino, S., & O'Connor, P. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10461 · Cited by 46
Longley, D. B., Latif, T., Boyer, J. L., ALLEN, W., Maxwell, P., & Johnston, P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70019-0 · Cited by 44
Shen, P., Reineke, L. C., Knutsen, E., Chen, M., Pichler, M., Ling, H. Y., & Călin, G. A. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12384 · Cited by 45
“The p53-deficient HCT116 cells (named HCT116 p53 / ) were a gift from Bert Vogelstein’s laboratory (Bunz et al., 1999).”
MethodAllison, S. J., & Milner, J. (2003) · PubMed · Cited by 50
Shin, S. Y., Kim, C. G., Lim, Y., & Lee, Y. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216721 · Cited by 46
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2
Min, S., Kim, D., Heo, Y.-S., Kim, H. M., Kim, I., & Yoo, O.-J. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.11.010 · Cited by 42
da Silva, G. N., Marcondes, J. P. D. C., de Camargo, E. A., Passos, G. A. S., Sakamoto‐Hojo, E. T., & Salvadori, D. M. F. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.009322 · Cited by 42
Din, F. V. N., Stark, L. A., & Dunlop, M. G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602455 · Cited by 42
“In this study, we specifically investigated the effects of p53 on the NFkB-induced apoptotic response by use of HCT-116 cells with the p53 gene homozygously disrupted by targeted homologous recombination (Bunz et al, 1999).”
MethodHoskins, J., & Scott Butler, J. (2007) · Yeast · doi:10.1002/yea.1516 · Cited by 42
“Perhaps the strongest argument for the significance of RNA-based 5FU toxicity comes from experiments in which uridine, but not thymidine, relieved the cytotoxic and apoptotic effects of 5FU (Bunz et al., 1999; Engelbrecht et al., 1984; Linke et al., 1996; Pritchard et al., 1997).”
BackgroundResultRusz, O., Pál, M., Szilágyi, É., Rovó, L., Varga, Z., Tomisa, B., Fábián, G., Kovács, L., Nagy, O., Mózes, P., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0088-z · Cited by 45
Mbaveng, A. T., Wamba, B. E. N., Bitchagno, G. T. M., Tankeo, S. B., Çelik, İ., Atontsa, B. C. K., Nkuété, A. H. L., Kuete, V., & Efferth, T. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113884 · Cited by 41
Moon, J. Y., Cho, M., Ahn, K. S., & Cho, S. K. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.756529 · Cited by 42
“Mutations in the gene p53 contribute to 5-FU resistance and have profound effects on drug responses (18,19), with reduced induction of apoptosis and inhibition of the cell cycle (20,21).”
BackgroundDevelopment of Investigational Radiation Modifiers
Colevas, A. D., Brown, J. M., Hahn, S. M., Mitchell, J., Camphausen, K. A., & Coleman, C. N. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.646 · Cited by 41
VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS
Chang, F.-L., & Lai, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66150-2 · Cited by 45
p53 suppresses structural chromosome instability after mitotic arrest in human cells
Dalton, W. B., Yu, B., & Yang, V. W. (2010) · Oncogene · doi:10.1038/onc.2009.477 · Cited by 45
“Moreover, because short-term rates of apoptosis do not always correspond to long-term rates of survival (Bunz et al., 1999), we also determined the clonogenicity of these nocodazole-treated cells.”
Horiguchi, M., Koyanagi, S., Hamdan, A. M., Kakimoto, K., Matsunaga, N., Yamashita, C., & Ohdo, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2492 · Cited by 44
“Because cells deficient in p53 exhibit resistance to chemotherapeutic agents (34, 35), we exploredwhether the oscillation of p53 protein levels affects the susceptibility of tumor cells to chemotherapeutic agents.”
BackgroundDerouet, M. F., Wu, X., May, L. L., Yoo, B. H., Sasazuki, T., Shirasawa, S., Rake, J., & Rosen, K. V. (2007) · Neoplasia · doi:10.1593/neo.07217 · Cited by 42
“been published [30], the survival of p53 knockout cells in the presence of 5-FU, irinotecan hydrochloride, or sulindac”
BackgroundCDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40
The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer
Fakheri, H., Sajadi, M. A., Afrashteh, A., Ma, W., Xia, L., & Valilo, M. (2023) · Biochemia Medica · doi:10.11613/bm.2023.030504 · Cited by 41
“Long-term studies have shown that ER(-) tumours, which mainly have TP53 mutations, are more sensitive to chemotherapy, while ER(+) tumours with TP53 WT are often resistant to chemotherapy (84).”
BackgroundNguyen, D., Zajac‐Kaye, M., Rubinstein, L., Voeller, D. M., Tomaszewski, J. E., Kummar, S., Chen, A. P., Pommier, Y. G., Doroshow, J. H., & Yang, S. X. (2011) · Cell Cycle · doi:10.4161/cc.10.23.18170 · Cited by 41
Gajendran, B., Durai, P., Varier, K. M., & Chinnasamy, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115242 · Cited by 42
Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines
Lee, G., Lee, J., Son, C., & Lee, N. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3425-8 · Cited by 40
Roh, J.-L., Ko, J. H., Moon, S. J., Ryu, C. H., Choi, J. Y., & Koch, W. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.020 · Cited by 43
“The loss of p53 function is associated with tumorigenesis, therapeutic resistance, aggressive phenotype, and poor prognosis [11–14].”
L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells
Ayroldi, E., Petrillo, M. G., Bastianelli, A., Marchetti, M. C., Ronchetti, S., Nocentini, G., Ricciotti, L., Cannarile, L., & Riccardi, C. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.129 · Cited by 44
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
Cadamuro, M., Brivio, S., Spirlì, C., Joplin, R., Strazzabosco, M., & Fabris, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010149 · Cited by 43
“Functional defects in the pro-apoptotic transcription factor p53, which upregulates both intrinsic (Bax) and extrinsic (Fas) mediators of apoptosis, were originally associated with decreased sensitivity to 5-FU, in vitro [49], but no current evidence supports p53 status as a determinant of response to anticancer drugs.”
BackgroundTranscription factor RFX7 governs a tumor suppressor network in response to p53 and stress
Coronel, L., Riege, K., Schwab, K., Förste, S., Häckes, D., Semerau, L., Bernhart, S. H., Siebert, R., Hoffmann, S., & Fischer, M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab575 · Cited by 39
“Confirming previous results (88,89), depletion of p53 did not increase the viability.”
ResultXi, Y., Nakajima, G., Schmitz, J. C., Chu, E., & Ju, J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-68 · Cited by 42
“The induction of p53 will contribute a significant part for cell cycle arrest and apoptosis based on previous reports [34,35].”
Backgroundp53 and cancer therapy: a double-edged sword
McGill, G. G., & Fisher, D. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7861 · Cited by 39
“(2) analyze the importance of p53 status in the response of human colorectal tumor cells to different chemotherapeutic agents.”
Background
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.